TUTI 16

Drug Profile

TUTI 16

Alternative Names: Thymon Universal Tat Immunogen; TUTI-16

Latest Information Update: 22 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Thymon LLC
  • Developer Thymon
  • Class AIDS vaccines; Antibodies; Lipopeptides; Vaccines
  • Mechanism of Action Human immunodeficiency virus tat gene product inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV-1 infections

Most Recent Events

  • 22 Sep 2015 No recent reports on development identified - Phase-I/II for HIV-1 infections in USA (SC)
  • 30 Jun 2012 Thymon LLC completes a phase I/II trial in HIV-1 infections in USA (NCT01335191)
  • 11 Jan 2012 Thymon completes enrolment in its phase I/II trial for HIV-1 infections in USA (NCT01335191)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top